Updates & Insights Blog
This blog features current topics in cancer genomics research and news and updates from OCG. Let's continue the conversation on our Personal Genomics Podcast.
At the present time, all NIH-sponsored meetings are cancelled. We apologize for any inconvenience this may cause and appreciate your understanding.
-
Drs. Staudt and Kibbe discuss NCI’s major initiatives to improve both the accessibility and usability of cancer genomics data. Top among the NCI’s priorities are the Genomic Data Commons, a service that will bring together and harmonize cancer genomic data sets from NCI programs and non-NCI data submitters, and the Cancer Genomics Cloud Pilots.
-
Using a “team science” approach, CCG supports research in structural, functional, and computational genomics that provide data and resources to the cancer research community. CCG director Dr. Lou Staudt provides an update of the center's mission and goals.
-
Dr. Louis M. Staudt, who recently named the Director of the Center for Cancer Genomics (CCG), discusses objectives, challenges, and future directions for the center.
-
CCG's Office of Cancer Genomics (OCG) reflects on milestones of 2011, which include progress in three programs: Cancer Genome Characterization Initiative (CGCI), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and Cancer Target Discovery and Development (CTD²).
-
The HIV+ Tumor Molecular Characterization Project (H+TMCP) is a new initiative with the goal of understanding the effect of HIV infection on the development of certain cancers. Center for Cancer Genomics scientific leader Dr. Daniela Gerhard remarks on the opportunities addressed by this program and the general need for progress on HIV research.
-
CCG manages many programs aiming to enhance our understanding of the molecular mechanisms of cancer. The Cancer Target Discovery and Development (CTD2) Network is a new initiative tasked to bridge the gap between cancer genomics and precision oncology and the Cancer Genomic Characterization Initiative (CGCI) focuses on characterizing pediatric and rare adult cancers. In 2010, these programs were managed by CCG's then Office of Cancer Genomics.
-
The National Cancer Institute (NCI) has invested a significant portion of its American Recovery and Reinvestment Act (ARRA) funds in existing cancer genomics research programs, including The Cancer Genome Atlas (TCGA)
-
A 2010 note from Dr. Daniela Gerhard, Director of the Office of Cancer Genomics (OCG), then a part of the Center for Cancer Genomics. The letter welcomes cancer genomics researchers to learn about the goals and many projects of OCG.